mOTS-400s
UTTA CAR-T
Mechanism of mOTS-400s
1. Islam, S., Lee, B., Jiang, F., Kim, E. K., Ahn, S. C., & Hwang, T. H. (2020).
Engineering and Characterization of Oncolytic Vaccinia Virus Expressing Truncated Herpes Simplex Virus Thymidine Kinase. Cancers, 12(1), 228.
Engineering and Characterization of Oncolytic Vaccinia Virus Expressing Truncated Herpes Simplex Virus Thymidine Kinase. Cancers, 12(1), 228.
2. Islam, S., Hong, Y. M., Ornella, M., Ngabire, D., Jang, H., Cho, E., Kim, E. K., Hale, J., Kim, C. H., Ahn, S. C., Cho, M., & Hwang, T. H. (2020).
Engineering and Preclinical Evaluation of Western Reserve Oncolytic Vaccinia Virus Expressing A167Y Mutant Herpes Simplex Virus Thymidine Kinase.
Biomedicines, 8(10), 426
Engineering and Preclinical Evaluation of Western Reserve Oncolytic Vaccinia Virus Expressing A167Y Mutant Herpes Simplex Virus Thymidine Kinase.
Biomedicines, 8(10), 426
Mechanism of UTTA CAR-T
We are currently developing a CAR-T cell therapy targeting UTTA (Universal Tumor Targeting Antigen)
expressed on the surface of tumor cell membranes after administration of oncolytic-virus mOTS-400s.
expressed on the surface of tumor cell membranes after administration of oncolytic-virus mOTS-400s.
